Voyager Therapeutics (NASDAQ:VYGR) PT Raised to $28.00

Voyager Therapeutics (NASDAQ:VYGR) had its price target hoisted by Morgan Stanley from $21.00 to $28.00 in a note issued to investors on Friday, The Fly reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 9.80% from the stock’s current price.

A number of other analysts also recently weighed in on VYGR. BidaskClub downgraded shares of Zebra Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, May 8th. ValuEngine upgraded shares of Yelp from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. HC Wainwright increased their price target on shares of Cytokinetics from $21.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Wedbush reiterated an “outperform” rating and issued a $74.00 price target on shares of Tempur Sealy International in a research report on Tuesday, June 18th. Finally, Nomura increased their price target on shares of Voyager Therapeutics from $26.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $27.44.

Voyager Therapeutics stock opened at $25.50 on Friday. Voyager Therapeutics has a 1 year low of $7.76 and a 1 year high of $28.79. The firm has a market cap of $945.49 million, a P/E ratio of -9.27 and a beta of 2.57. The company’s 50-day simple moving average is $25.27.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($1.46). The business had revenue of $5.20 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative net margin of 804.55% and a negative return on equity of 129.67%. On average, analysts forecast that Voyager Therapeutics will post -2.86 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its stake in Voyager Therapeutics by 1.0% during the 1st quarter. Acadian Asset Management LLC now owns 46,500 shares of the company’s stock worth $890,000 after purchasing an additional 469 shares in the last quarter. Weiss Multi Strategy Advisers LLC increased its stake in Voyager Therapeutics by 10.0% during the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 11,000 shares of the company’s stock worth $103,000 after purchasing an additional 1,000 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Voyager Therapeutics by 15.8% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,174 shares of the company’s stock worth $252,000 after purchasing an additional 1,794 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in Voyager Therapeutics by 22.2% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 12,100 shares of the company’s stock worth $259,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Tocqueville Asset Management L.P. increased its stake in Voyager Therapeutics by 8.7% during the 1st quarter. Tocqueville Asset Management L.P. now owns 30,425 shares of the company’s stock worth $582,000 after purchasing an additional 2,425 shares in the last quarter. 73.78% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Read More: Asset Allocation

The Fly

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.